BioCentury | May 11, 2015
Product Development

Check your effectors

...least four companies have disclosed preclinical programs targeting Kv1.3: Axxam S.p.A. , Bionomics Ltd. , conoGenetix biosciences GmbH...
...S.p.A., Milan, Italy Bionomics Ltd. (ASX:BNO; OTCQX:BMICY), Thebarton, Australia Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. conoGenetix biosciences GmbH...
BioCentury | Apr 17, 2014
Distillery Therapeutics

Indication: Inflammation

...have ShK-186 in Phase I testing to treat multiple sclerosis (MS), lupus and psoriatic arthritis. conoGenetix biosciences GmbH...
BioCentury | Jun 6, 2013
Targets & Mechanisms

Watching obesity on a new channel

...effector-memory T cells. 2 Indeed, four companies have KCNA3 inhibitors in preclinical development for autoimmunity: conoGenetix biosciences GmbH...
...Milan, Italy Bionomics Ltd. (ASX:BNO; OTCBB:BMICY), Thebarton, SA, Australia Circassia Ltd. , Oxford, U.K. conoGenetix biosciences GmbH...
BioCentury | Apr 30, 2012
Financial News

conoGenetix completes venture financing

conoGenetix biosciences GmbH , Martinsried, Germany Business: Autoimmune Date completed: 4/18/12 Type: Venture financing Raised: More than €1.5 million ($2 million) Investors: Mey Capital Matrix; BioM Note: The company said it raised more than €1.5 million...
BioCentury | Apr 24, 2012
Financial News

conoGenetix raises EUR 1.5 million in Series A

...$2 million) in a series A round led by Mey Capital Matrix. BioM also participated. conoGenetix...
Items per page:
1 - 5 of 5
BioCentury | May 11, 2015
Product Development

Check your effectors

...least four companies have disclosed preclinical programs targeting Kv1.3: Axxam S.p.A. , Bionomics Ltd. , conoGenetix biosciences GmbH...
...S.p.A., Milan, Italy Bionomics Ltd. (ASX:BNO; OTCQX:BMICY), Thebarton, Australia Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. conoGenetix biosciences GmbH...
BioCentury | Apr 17, 2014
Distillery Therapeutics

Indication: Inflammation

...have ShK-186 in Phase I testing to treat multiple sclerosis (MS), lupus and psoriatic arthritis. conoGenetix biosciences GmbH...
BioCentury | Jun 6, 2013
Targets & Mechanisms

Watching obesity on a new channel

...effector-memory T cells. 2 Indeed, four companies have KCNA3 inhibitors in preclinical development for autoimmunity: conoGenetix biosciences GmbH...
...Milan, Italy Bionomics Ltd. (ASX:BNO; OTCBB:BMICY), Thebarton, SA, Australia Circassia Ltd. , Oxford, U.K. conoGenetix biosciences GmbH...
BioCentury | Apr 30, 2012
Financial News

conoGenetix completes venture financing

conoGenetix biosciences GmbH , Martinsried, Germany Business: Autoimmune Date completed: 4/18/12 Type: Venture financing Raised: More than €1.5 million ($2 million) Investors: Mey Capital Matrix; BioM Note: The company said it raised more than €1.5 million...
BioCentury | Apr 24, 2012
Financial News

conoGenetix raises EUR 1.5 million in Series A

...$2 million) in a series A round led by Mey Capital Matrix. BioM also participated. conoGenetix...
Items per page:
1 - 5 of 5